Search research articles
Contact Us
Filters
Showing results (161-170 of 176) with videos related to
Page
of 18
Sort By:
Ebiomedicine
|
June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Yunda Huang, Lily Zhang, Huub Gelderblom, et al.
Lancet (London, England)
|
December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Kayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 8, 2020
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, et al.
The Journal of Infectious Diseases
|
April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Nature Medicine
|
May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Boris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Science (New York, N.Y.)
|
August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys
Peter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Nature Medicine
|
October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Kathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Cell Host & Microbe
|
January 11, 2019
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Christine A Bricault, Karina Yusim, Michael S Seaman, et al.
JAMA
|
March 11, 2021
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, et al.
Journal of the National Cancer Institute
|
August 21, 2003
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
T J Key, P N Appleby, G K Reeves, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 176) with videos related to
Sort By:
Page
of 18
Ebiomedicine
|
June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Yunda Huang, Lily Zhang, Huub Gelderblom, et al.
Lancet (London, England)
|
December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Kayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 8, 2020
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, et al.
The Journal of Infectious Diseases
|
April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Nature Medicine
|
May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Boris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Science (New York, N.Y.)
|
August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys
Peter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Nature Medicine
|
October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Kathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Cell Host & Microbe
|
January 11, 2019
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Christine A Bricault, Karina Yusim, Michael S Seaman, et al.
JAMA
|
March 11, 2021
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, et al.
Journal of the National Cancer Institute
|
August 21, 2003
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
T J Key, P N Appleby, G K Reeves, et al.
Page
of 18